Exclusive-US FDA cleared pricey rare disease drug over reviewer objections

FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, while safe, was no more effective than a placebo, a Reuters review of agency documents found. The urgent need among patients, along with some signs of improved motor skills, helped drive the agency's decision, the documents show.